ARVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arvinas Inc (ARVN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price declines and insider selling, the stock presents a compelling opportunity due to positive insider buying, strong analyst support with raised price targets, and upcoming clinical data readouts that could act as catalysts. The technical indicators and options sentiment suggest potential for a rebound.
The stock is currently trading at $12.48, with a significant regular market decline of -7.42%. The MACD is negative and expanding, indicating bearish momentum, while RSI at 30.984 is neutral. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting a potential recovery. Key support lies at $12.546, close to the current price, with resistance at $14.258.
Insider buying: Director Briggs Morrison purchased 20,000 shares at $13.40, reflecting confidence in the company's future.
Analyst upgrades: Multiple analysts raised price targets, with the highest at $20, citing strong cash reserves and upcoming clinical data readouts.
Upcoming catalysts: ARV-102 data in Parkinson's disease to be presented in March, with additional trials planned for 2026.
Insider selling: Insider selling increased by 36,356.22% over the last month, which could indicate caution.
Recent financial performance: Revenue dropped significantly (-83.95% YoY) in Q4 2025, although net income and EPS improved.
In Q4 2025, revenue dropped to $9.5M (-83.95% YoY), but net income improved to -$67.4M (+49.45% YoY), and EPS increased to -1.04 (+65.08% YoY). Gross margin remained stable at 100%. The company has cash reserves to fund operations into the second half of 2028.
Analysts are generally bullish on ARVN, with multiple firms raising price targets recently. The highest target is $20, and the lowest is $11. Analysts cite strong cash reserves, upcoming clinical data, and a pivotal 2026 as reasons for optimism.
